Furthermore, Figure S1B shows that prostate tumors with low Gleason score and stage (VI, N0) expressed a higher level of CRYM mRNA as compared to tumors with higher Gleason score and pathological stage (VII and IX, N1+) (Vanaja cohort; P = .00024, Luo 2 cohort; P = .007 and LaTullipe cohort; P = .015). This evidence concerns the gene CRYM and prostate neoplasm.